Microbiome Manufacturing Market Size is valued at USD 27.3 Mn in 2023 and is predicted to reach USD 84.8 Mn by the year 2031 at a 15.4% CAGR during the forecast period for 2024-2031.
Microbiome manufacture integrates sophisticated biotechnological techniques with a deep comprehension of microbial ecosystems, rendering it a state-of-the-art field of advancement with extensive implications for medicine, nutrition, and general health. The microbiome manufacturing market is at the cutting edge of scientific progress because it focuses on changing and using microbiomes for a wide range of reasons. At its core, this market is about making products and medicines based on microbiomes. These can be anything from medical treatments to consumer goods. Microbiomes are complex groups of microorganisms that live in different environments. They are becoming more and more important for human health, crops, and the long-term health of the environment.
Live biotherapeutic products (LBP), a class of microbiome therapy, involve the use of live microorganisms, such as bacteria, viruses, or fungi, to prevent or treat various disease conditions. LBPs are specifically designed for therapeutic purposes and are regulated as medicinal products or biologics in many countries. Live biotherapeutic products (LBP), a class of microbiome therapy, involve the use of live microorganisms, such as bacteria, viruses, or fungi, to prevent or treat various disease conditions.
However, outsourcing microbiome therapeutics manufacturing to CMOs and CDMOs has emerged as a lucrative option for human microbiome therapy developers to overcome existing manufacturing issues. Furthermore, increasing R&D activities, government steps to use effective components for production, and investments by key players are factors expected to create lucrative revenue growth gateways for players operating in the global microbiome manufacturing market over the forecast period.
Competitive Landscape
Some Major Key Players In The Microbiome Manufacturing Market:
- Arranta Bio
- BacThera
- Biose
- BJP Laboratories
- Capsugel
- Cerbios-Pharma
- Hansen
- Inpac Probiotics
- NIZO
- WACKER
- Winclove
- Other Market Players
Market Segmentation:
The Microbiome Manufacturing Market is segmented into type of product manufactured, formulation, primary packaging used, scale of operation and company size. By Type of Product Manufactured, the market comprises API, FDF. According to the Formulation, market is segmented into solid, Liquid, and Others. As per the Primary Packaging Used, market is categorized into Blister Packs, Glass / Plastic Bottles, Pouches / Sachets, and Vials. According to the Scale of Operation, market segmentation includes Clinical and Commercial. As per Company Size, the market is divided into Small, Mid-sized, Large, and Very Large.
The API Segment Is A Major Contributor To The Microbiome Manufacturing Market Based On The Product Manufactured.
In the Microbiome Manufacturing Market, the API (Active Pharmaceutical Ingredient) segment is a major contributor mainly because of its crucial role in the production of microbiome-based therapies. APIs serve as the core component responsible for the therapeutic activity of these treatments. With increasing research focusing on microbiome-based interventions for various diseases, such as gastrointestinal disorders and immune-related conditions, the demand for APIs tailored to these therapies is rising. Moreover, advancements in microbiome research and manufacturing technologies are driving the growth of the API segment, further solidifying its position as a key player in the microbiome manufacturing landscape.
The Blister Packs Segment Witnessed Growth At A Rapid Rate.
The Blister Packs segment is experiencing rapid growth in the Microbiome Manufacturing Market due to its advantages in preserving and delivering microbiome-based therapeutics. Blister packs offer superior protection against environmental factors, ensuring the stability and efficacy of live microbial products. Additionally, their convenience and dose accuracy enhance patient compliance and enable easy administration. As microbiome-based therapies gain traction for various medical conditions, including gastrointestinal disorders and immune-related diseases, the demand for blister packs as a preferred packaging solution is surging. This trend underscores the pivotal role of packaging innovations in driving the expansion of the microbiome manufacturing industry.
In The Region, The North America Microbiome Manufacturing Market Holds A Significant Revenue Share.
The North America Microbiome Manufacturing Market is expected to register the greatest market share in terms of revenue in the near future. This can be attributed to an increase in lifestyle illnesses, a greater stress on human microbiome therapeutics, and increased technological achievements in the human microbiome and next-generation sequencing. In addition, huge government research projects, such as the Human Microbiome Project in the USA, have boosted microbiome research. Many firms are also developing microbiome medicines. In addition, Europe is expected to grow at a rapid rate in the global Microbiome Manufacturing Market due to increasing concerns related to the environment, rapid urbanization, government initiatives, and increasing funding in various industries.
Recent Developments:
- In Sept 2020, Luina Bio stated its intention to increase its capacity in order to satisfy the growing demand in the microbiome and recombinant biopharma markets. The company expanded its service offering to include additional clinical initiatives that necessitated the use of small-scale GMP facilities.
Microbiome Manufacturing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 27.3 Mn |
|
Revenue Forecast In 2031 |
USD 84.8 Mn |
|
Growth Rate CAGR |
CAGR of 15.4% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type Of Product Manufactured, Formulation, Primary Packaging Used, Scale Of Operation And Company Size |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Arranta Bio, BacThera, Biose, BJP Laboratories, Capsugel, Cerbios-Pharma, Chr. Hansen, Inpac Probiotics, NIZO, WACKER and Winclove |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
